EWG Elevate Inc. Invests $480,000 in ADMA Biologics, Inc. (NASDAQ:ADMA)

EWG Elevate Inc. bought a new stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) in the fourth quarter, Holdings Channel reports. The fund bought 28,000 shares of the biotechnology company’s stock, valued at approximately $480,000.

Several other hedge funds also recently added to or reduced their stakes in ADMA. Quest Partners LLC acquired a new stake in shares of ADMA Biologics during the 2nd quarter valued at about $29,000. Hollencrest Capital Management purchased a new position in ADMA Biologics during the third quarter worth approximately $30,000. Larson Financial Group LLC purchased a new position in ADMA Biologics during the third quarter worth approximately $31,000. GAMMA Investing LLC grew its holdings in ADMA Biologics by 106.6% in the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 967 shares during the period. Finally, National Bank of Canada FI purchased a new stake in shares of ADMA Biologics in the third quarter valued at approximately $35,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CFO Brad L. Tade sold 15,000 shares of the stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total value of $317,250.00. Following the completion of the transaction, the chief financial officer now directly owns 199,433 shares in the company, valued at approximately $4,218,007.95. This represents a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 3.70% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

ADMA has been the topic of a number of research analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $20.00 price target on shares of ADMA Biologics in a research note on Friday, September 20th. HC Wainwright lifted their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Finally, Raymond James upped their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research report on Friday, November 8th.

ADMA Biologics Stock Performance

Shares of ADMA stock opened at $18.56 on Monday. ADMA Biologics, Inc. has a fifty-two week low of $4.77 and a fifty-two week high of $23.64. The firm has a market capitalization of $4.39 billion, a P/E ratio of 66.29 and a beta of 0.76. The stock’s fifty day moving average is $19.39 and its two-hundred day moving average is $17.15. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The firm had revenue of $119.84 million for the quarter, compared to analyst estimates of $107.25 million. During the same period in the previous year, the business posted $0.01 earnings per share. Research analysts expect that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.